Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.

NCT07358416 | Active Not Recruiting

• 1 other identifier: ComplVasc2025Retro
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this retrospective clinical trial is to find out association antiplatelet and anticoagulant therapy with perioperative complications in non-cardiac vascular surgery in patients . The main questions it aims to answer are: Does the use of antiplatelet agents and anticoagulants affect the development of complications in the perioperative period during operations on the main arteries? Does discontinuing antiplatelet and anticoagulant medications affect the development of perioperative complications in major artery surgeries?? Researchers will compare with patients who didn't use antiplatelets and anticoagulant drugs to see ift he incidence of complications comparable? This is a retrospective study based on the analysis of medical records (case histories).

Conditions

Thrombosis; Bleeding; Cerebral Hypoxia During and/or Resulting From A Procedure

Keywords

Vascular surgery; Antiplatelet; Anticoagulants; complication; trombosis; bleeding

Outcome Measures

Primary Outcomes (1)

• Bleeding

  Case of bleeding or haematoma development

  First 24 hours after operation

Secondary Outcomes (1)

• Trombosis

  First 24 hours after operation

Study Arms (3)

Control

Patients who did not take antiplatelet agents and anticoagulants

Antiplatelet and anticoagulants

Patients who use antiplatelet agents and anticoagulants until the operation day

Drug: Aspirin; Drug: Clopidogrel; Drug: Ticagrelor; Drug: Dabigatran; Drug: Rivaroxaban; Drug: Apixaban; Drug: Warfarin; Drug: aspirin + clopidogrel; Drug: Aspirin + Ticagrelor; Drug: Aspirin + Apixaban; Drug: Aspirin + rivaroxaban; Drug: Clopidogrel + Apixaban; Drug: Clopidogrel + Rivaroxaban

Discontinuation of antiplatelet and anticoagulants

Patients who discontinuate antiplatelet agents and anticoagulants until the operation day

Interventions

Rivaroxaban DRUG

Patients who take rivaroxaban until the operation day

Antiplatelet and anticoagulants

Apixaban DRUG

Patients who take apixaban until the operation day

Antiplatelet and anticoagulants

Warfarin DRUG

Patients who take warfarin until the operation day

Antiplatelet and anticoagulants

aspirin + clopidogrel DRUG

Patients who take aspirin and clopidogrel until the operation day

Antiplatelet and anticoagulants

Aspirin + Ticagrelor DRUG

Patients who take aspirin and ticagrelor until the operation day

Antiplatelet and anticoagulants

Aspirin + Apixaban DRUG

Patients who take aspirin and apixaban until the operation day

Antiplatelet and anticoagulants

Aspirin + rivaroxaban DRUG

Patients who take aspirin and rivaroxaban until the operation day

Antiplatelet and anticoagulants

Clopidogrel + Apixaban DRUG

Patients who take clopidogrel and apixaban until the operation day

Antiplatelet and anticoagulants

Clopidogrel + Rivaroxaban DRUG

Patients who take clopidogrel and rivaroxaban until the operation day

Antiplatelet and anticoagulants

Aspirin DRUG

Patients who take aspirin until the operation day

Antiplatelet and anticoagulants

Clopidogrel DRUG

Patients who take clopidogrel until the operation day

Antiplatelet and anticoagulants

Ticagrelor DRUG

Patients who take ticagrelor until the operation day

Antiplatelet and anticoagulants

Dabigatran DRUG

Patients who take dabigatran until the operation day

Antiplatelet and anticoagulants

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with surgical treatment of atherosclerotic lesions of the main arteries.

You may qualify if:

• Patients who received surgical treatment on the main arteries.

You may not qualify if:

• Patients who received surgical treatment on the main veins.

Sponsors & Collaborators

• Petrovsky National Research Centre of Surgery: lead

Study Sites (1)

NRCS Petrovsky

Moscow, 119991, Russia

Location

MeSH Terms

Conditions

Thrombosis; Hemorrhage

Interventions

Aspirin; Clopidogrel; Ticagrelor; Dabigatran; Rivaroxaban; apixaban; Warfarin

Condition Hierarchy (Ancestors)

Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Salicylates; Hydroxybenzoates; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Ticlopidine; Thienopyridines; Thiophenes; Sulfur Compounds; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Adenosine; Purine Nucleosides; Purines; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Ribonucleosides; Benzimidazoles; Morpholines; Oxazines; 4-Hydroxycoumarins; Coumarins; Benzopyrans; Pyrans

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 14, 2026
• First Posted: January 22, 2026
• Study Start: May 1, 2025
• Primary Completion: February 12, 2026
• Study Completion: February 28, 2026
• Last Updated: January 22, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will share

Locations

RU (1)